Important Safety Information
Caregiver Resources
If someone you love has non-Hodgkin’s lymphoma (NHL), there are organizations and support groups for you. They can help you connect with others, share your experiences, and learn all you can about lymphoma. Below is a selection of resources for caregivers. To see the full list of organizations and contact information, click here.
Genentech USA and Biogen Idec are not affiliated with any of the organizations on this page. The information provided by Genentech, Biogen Idec, or these organizations is meant for informational purposes only and is not meant to replace your physician’s medical advice.
Leukemia and Lymphoma Society (LLS): For Caregivers
Find online and print information with added resources to help lymphoma caregivers give and receive support.
Go now
Lymphoma Research Foundation (LRF): Care for Caregivers
Visit the LRF’s caregiver page to connect with other caregivers, access a live help line, and more.
Go now
American Cancer Society (ACS): A “Care Package” for the Caregiver
Visit this page for a list of 15 quick links for caregivers within the ACS Web site and a caregiver discussion board.
Go now
National Cancer Institute (NCI): Caring for the Caregiver
Visit the NCI’s caregiver’s section. It includes information and advice to help you care for your friend or loved one and yourself.
Go now
This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.
Indications and Important Safety Information
RITUXAN® (Rituximab) is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
People with serious infections should not receive RITUXAN.
Important Safety Information:
- RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
- RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
- The most common side effects of RITUXAN seen in patients with non-Hodgkin’s lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
- Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor
Please see full Prescribing Information, including Medication Guide.
